Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ligand Pharmaceuticals (LGND) Short-term Investments (2016 - 2025)

Ligand Pharmaceuticals' Short-term Investments history spans 16 years, with the latest figure at $177.4 million for Q2 2025.

  • For Q2 2025, Short-term Investments changed N/A year-over-year to $177.4 million; the TTM value through Jun 2025 reached $177.4 million, changed N/A, while the annual FY2024 figure was $183.9 million, N/A changed from the prior year.
  • Short-term Investments for Q2 2025 was $177.4 million at Ligand Pharmaceuticals, up from $160.9 million in the prior quarter.
  • Across five years, Short-term Investments topped out at $321.6 million in Q4 2021 and bottomed at $117.3 million in Q3 2022.
  • The 5-year median for Short-term Investments is $180.6 million (2024), against an average of $203.6 million.
  • The largest annual shift saw Short-term Investments decreased 11.55% in 2021 before it plummeted 48.11% in 2022.
  • A 5-year view of Short-term Investments shows it stood at $321.6 million in 2021, then tumbled by 48.11% to $166.9 million in 2022, then increased by 16.22% to $193.9 million in 2023, then dropped by 5.2% to $183.9 million in 2024, then dropped by 3.54% to $177.4 million in 2025.
  • Per Business Quant, the three most recent readings for LGND's Short-term Investments are $177.4 million (Q2 2025), $160.9 million (Q1 2025), and $183.9 million (Q4 2024).